Evidence map›Paper›PMID 34285006›Full record

ArticleBMJ open2021

Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS).

Ka-Chun Li, Maoyi Tian, Bruce Neal, Liping Huang, Jie Yu, Yishu Liu, Xuejun Yin, Xinyi Zhang, Yangfeng Wu, Nicole Li and 16 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02092090 (A LARGE-SCALE CLUSTER RANDOMIZED TRIAL TO DETERMINE THE EFFECTS OF SODIUM REDUCTION ON STROKE), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02092090 nacompletednot on this map

A LARGE-SCALE CLUSTER RANDOMIZED TRIAL TO DETERMINE THE EFFECTS OF SODIUM REDUCTION ON STROKE: THE CHINA SALT SUBSTITUTE AND STROKE STUDY (SSaSS)

TypeinterventionalSponsorThe George InstituteRan2014 to 2020Enrolled20,996ConditionsStrokeArmsDietary sodium reduction
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 10 institutions in 4 countries.

Ka-Chun LiThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia kli@georgeinstitute.org.au.ORCID 0000-0002-5788-528X
Maoyi TianThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Bruce NealThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Liping HuangThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Jie YuThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-7401-7580
Yishu LiuThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Xuejun YinThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0001-8446-9591
Xinyi ZhangThe George Institute for Global Health at Peking University Health Science Center, Beijing, China.
Yangfeng WuThe George Institute for Global Health at Peking University Health Science Center, Beijing, China.
Nicole LiGeorge Clinical, Sydney, New South Wales, Australia.
Paul ElliottSchool of Public Health, Imperial College London, London, UK.ORCID 0000-0002-7511-5684
Lijing YanThe George Institute for Global Health at Peking University Health Science Center, Beijing, China.
Darwin LabartheFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Zhixin HaoThe George Institute for Global Health at Peking University Health Science Center, Beijing, China.
Jingpu ShiDepartment of Evidence-based Medicine, First Hospital of China Medical University, Shenyang, China.
Xiangxian FengSchool of Public Health, Changzhi Medical College, Changzhi, China.
Jianxin ZhangDepartment of Non-communicable Disease Prevention and Control, Center for Disease Control of Hebei Province, Shijiazhuang, China.
Yuhong ZhangSchool of Public Health, Ningxia Medical University, Yinchuan, China.
Ruijuan ZhangSchool of Public Health, Xi'an Jiaotong University, Xi'an, China.
Bo ZhouDepartment of Evidence-based Medicine, First Hospital of China Medical University, Shenyang, China.
Zhifang LiSchool of Public Health, Changzhi Medical College, Changzhi, China.
Jixin SunDepartment of Non-communicable Disease Prevention and Control, Center for Disease Control of Hebei Province, Shijiazhuang, China.
Yi ZhaoSchool of Public Health, Ningxia Medical University, Yinchuan, China.
Yan YuSchool of Public Health, Xi'an Jiaotong University, Xi'an, China.
Lei SiThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-3044-170X
Thomas LungThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0001-9978-6311
Peking University · CNUNSW Sydney · AUChangzhi Medical College · CNFirst Hospital of China Medical University · CNHebei Provincial Center for Disease Control and Prevention · CNNingxia Medical University · CNXi'an Jiaotong University · CNImperial College London · GBNorthwestern University · USThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. Reducing dietary salt consumption is a potentially cost-effective way to reduce blood pressure and the burden of CVD. To date, economic evidence has focused on sodium reduction in food industry or processed food with blood pressure as the primary outcome. This study protocol describes the planned within-trial economic evaluation of a low-sodium salt substitute intervention designed to reduce the risk of stroke in China. METHODS AND ANALYSES: The economic evaluation will be conducted alongside the Salt Substitute and Stroke Study: a 5-year large scale, cluster randomised controlled trial. The outcomes of interest are quality of life measured using the EuroQol-5-Dimensions and major adverse cardiovascular events. Costs will be estimated from a healthcare system perspective and will be sought from the routinely collected data available within the New Rural Cooperative Medical Scheme. Cost-effectiveness and cost-utility analyses will be conducted, resulting in the incremental cost-effectiveness ratio expressed as cost per cardiovascular event averted and cost per quality-adjusted life year gained, respectively. ETHICS AND DISSEMINATION: The trial received ethics approval from the University of Sydney Ethics Committee (2013/888) and Peking University Institutional Review Board (IRB00001052-13069). Informed consent was obtained from each study participant. Findings of the economic evaluation will be published in a peer-reviewed journal and presented at international conferences. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT02092090).

Indexed as

Quality of LifeStrokeChinaCost-Benefit AnalysisHumansQuality-Adjusted Life YearsRandomized Controlled Trials as Topiccardiac epidemiologyhealth economicsnutrition & dieteticspublic healthstroke medicine

Identifiers

PMID34285006
PMCPMC8292808
OpenAlexW3183803647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.